Clinical Trials Browser

Phase 2 × Fallopian Tube Neoplasms × catumaxomab × Clear all

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00377429 2012-07-19

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Phase 2 Completed

47 enrolled 11 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00189345 2006-11-08

Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

Phase 2 Completed

44 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Clinical Trials

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients